Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2004-09-01
Last Posted Date
2017-02-09
Lead Sponsor
Children's Oncology Group
Target Recruit Count
1970
Registration Number
NCT00002744
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Children's Hospital of Columbus, Columbus, Ohio, United States

🇺🇸

Children's Hospital and Medical Center - Seattle, Seattle, Washington, United States

and more 31 locations

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Leukemia
Lymphoma
First Posted Date
2004-08-30
Last Posted Date
2013-06-20
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00002471
Locations
🇺🇸

Kaplan Cancer Center, New York, New York, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2
Conditions
Leukemia
First Posted Date
2004-08-23
Last Posted Date
2013-09-20
Lead Sponsor
Grupo Argentino de Tratamiento de la Leucemia Aguda
Registration Number
NCT00002499
Locations
🇦🇷

Grupo Argentino de Tratamiento de la Leucemia Aguda, Buenos Aires, Argentina

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-23
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
30
Registration Number
NCT00002674
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-11
Last Posted Date
2013-06-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
40
Registration Number
NCT00002609
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-11
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
25
Registration Number
NCT00002865
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

First Posted Date
2004-08-09
Last Posted Date
2013-06-19
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00004215
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-08-05
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
3
Registration Number
NCT00003957
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
Neutropenia
Thrombocytopenia
First Posted Date
2004-07-29
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
50
Registration Number
NCT00002665
Locations
🇺🇸

CCOP - Dayton, Kettering, Ohio, United States

🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

🇺🇸

Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 80 locations

Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

First Posted Date
2004-07-29
Last Posted Date
2014-07-24
Lead Sponsor
Children's Oncology Group
Target Recruit Count
242
Registration Number
NCT00002618
Locations
🇺🇸

San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States

🇺🇸

Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States

🇨🇭

Clinique de Pediatrie, Geneva, Switzerland

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy